1. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely, & Jones, 1817.
2. Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48(8): 938-942.
3. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43(11):2227-2229.
4. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003; 60(11):1756-1761.
5. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995; 45(4):669-671.
6. Aarsland D, Larsen JP, Karlsen K, et al. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14(10):866-874.
Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 2002; 59(11):1724-1728.
Aarsland D, Tandberg E, Larsen JP, et al. Frequency of dementia in Parkinson disease. Arch Neurol 1996; 53(6):538-542.
Fernandez HH, Lapane KL. Predictors of mortality among nursing home residents with a diagnosis of Parkinson's disease. Med Sci Monit 2002; 8(4):CR241-246. Hughes TA, Ross HF, Mindham RH, et al. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004; 110(2):118-123. de Lau LM, Schipper CM, Hofman A, et al. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol 2005; 62(8):1265-1269. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association, 1994. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123 (Pt 4):733-745.
Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996; 53(12):1265-1268.
Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70(6):734-738. Chou KL, Messing S, Oakes D, et al. Drug-induced psychosis in parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharma-col 2005; 28(5):215-219.
Factor SA, Molho ES, Podskalny GD, et al. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995; 65:115-138.
Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol 1993; 60:703-706.
Marsh L, Williams JR, Rocco M, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004; 63(2):293-300.
Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991; 39(7):708-716.
Fernandez HH, Friedman JH. The role of atypical antipsychotics in the treatment of movement disorders. CNS drugs 1999; 11(6):467-483.
Fischer P, Danielczyk W, Simanyi M, et al. Dopaminergic psychosis in advanced Parkinson's disease. Adv Neurol 1990; 53:391-397.
Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982; 139(4):494-497.
Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64(4):533-535.
Tousi B, Frankel M. Olfactory and visual hallucinations in Parkinson's disease. Parkin-sonism Relat Disord 2004; 10(4):253-254.
Cahn-Weiner DA, Grace J, Ott BR, et al. Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's disease. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15(2):79-87.
Cummings JL. The Neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology 1997; 48(5 suppl 6):S10-S16.
Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48(suppl:9-15. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry 1989; 155(suppl. 7):59-67. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa, 1984.
Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville, Md.: Alcohol, Drug Abuse and Mental Health Administration, 1976.
35. Friedberg G, Zoldan J, Weizman A, et al. Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol 1998; 21(5):280-284.
36. Klawans HL, Goetz C, Nausieda PA, et al. Levodopa-induced dopamine receptor hypersensitivity. Trans Am Neurol Assoc 1977; 102:80-83.
37. Rondot P, de Recondo J, Coignet A, et al. Mental disorders in Parkinson's disease after treatment with L-DOPA. Adv Neurol 1984; 40:259-269.
38. Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings). J Neural Transm 1975; 37(2):175-182.
39. Nausieda PA, Tanner CM, Klawans HL. Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. Adv Neurol 1983; 37:23-32.
40. Melamed E, Zoldan J, Friedberg G, et al. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Adv Neurol 1996; 69:545-550.
41. Diederich NJ, Goetz CG, Raman R, et al. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol 1998; 21(5):289-295.
42. Matsui H, Udaka F, Tamura A, et al. The relation between visual hallucinations and visual evoked potential in Parkinson disease. Clin Neuropharmacol 2005; 28(2):79-82.
43. Diederich NJ, Alesch F, Goetz CG. Visual hallucinations induced by deep brain stimulation in Parkinson's disease. Clin Neuropharmacol 2000; 23(5):287-289.
44. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 2004; 63(8):1409-1416.
45. Aarsland D, Larsen JP, Cummins JL, et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999; 56(5):595-601.
46. Arnulf I, Bonnet AM, Damier P, et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 2000; 55(2):281-288.
47. Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenom-enological survey. J Neurol Neurosurg Psychiatry 2001; 70(6):727-733.
48. Comella CL, Tanner CM, Ristanovic RK. Polysomnography sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 1993; 34(5):710-714.
49. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA 2000; 284(15):1931-1938.
50. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342(20):1484-1491.
51. Klein C, Kompf D, Pulkowski U, et al. A study of visual hallucinations in patients with Parkinson's disease. J Neurol 1997; 244(6):371-377.
52. Merims D, Shabtai H, Korczyn AD, et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm 2004; 111(10-11):1447-1453.
53. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15(2):201-211.
54. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294(15):1934-1943.
55. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991; 324(11):746-754.
56. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340(10):757-763.
57. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75(5):689-695.
58. Wolters EC, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40(5):832-834.
59. French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999, 353(9169):2041-2042.
61. Klein C, Gordon J, Pollak L, et al. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuropharmacol 2003; 26(1):8-11.
62. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59(suppl 3):3-7.
64. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60(2):107-115.
65. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 1999; 52(4):782-785.
66. Ellis T, Cudkowicz ME, Sexton PM, et al. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000; 12(3):364-369.
67. Workman RH, Jr., Orengo CA, Bakey AA, et al. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neu-rosci 1997; 9(4):594-597.
68. Meco G, Alessandria A, Bonifati V, et al. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 1994; 343(8909):1370-1371.
69. Allen RL, Walker Z, D'Ath PJ, et al. Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet 1995; 346(8968):185.
70. McKeith IG, Ballard CG, Harrison RW. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 1995; 346(8976):699.
71. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease. Lancet 1994; 344(8923):681.
72. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56(12):556-559.
73. Meco G, Alessandri A, Giustini P, et al. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov Disord 1997; 12(4):610-612.
74. Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000; 15(2):301-304.
75. Mohr E, Mendis T, Hildebrand K, et al. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000; 15(6): 1230-1237.
76. Moore NA, Tye NC, Axton MS, et al. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992; 262(2):545-551.
77. Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997; 58(suppl 10):7-12.
78. Wolters EC, Jansen EN, Tuynman-Qua HG, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47(4):1085-1087.
79. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 2003; 26(9):643-659.
80. Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55(6):789-794.
81. Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002; 17(5):1031-1035.
82. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002; 52(5):438-445.
83. Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson's disease. Mov Disord 2002; 17(suppl 4):S120-S127.
84. Sailer CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993; 112(2-3):285-292.
85. Reddy S, Factor SA, Molho ES, et al. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002; 17(4): 676-681.
86. Fernandez HH, Trieschmann ME, Burke MA, et al. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003; 18(5):510-514.
87. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27(4):153-156.
88. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20(8):958-963.
89. Rabey JM, Prokhorov T, Miniovich A, et al. The effect of quetiapine in Parkinson's disease (PD) psychotic patients: A double-blind labeled study of three months duration. Mov Disord 2005; 20(suppl 10):S46.
90. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003; 64(suppl 19):6-12.
91. Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005; 66(suppl 6):5-10.
92. Gomez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol 2005; 28(3):111-114.
93. Oechsner M, Korchounov A. Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease? Hum Psychopharmacol 2005; 20(3):203-205.
94. Weiden PJ, Iqbal N, Mendelowitz AJ, et al. Best clinical practice with ziprasidone: update after one year of experience. J Psychiatr Pract 2002; 8(2):81-97.
95. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004; 27(1):4-5.
96. Friedman JH, Berman RM, Carson W, et al. Low dose aripiprazole for the treatment of drug induced psychosis in Parkinson's disease patients. Mov Disord 2005; 20(suppl 10):S92.
97. White A, Corn TH, Feetham C, et al. Ondansetron in treatment of schizophrenia. Lancet 1991; 337(8750):1173.
98. Zoldan J, Friedberg G, Goldberg-Stern H, et al. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993; 341(8844):562-563.
99. Zoldan J, Friedberg G, Livneh M, et al. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45(7):1305-1308.
100. Eichhorn TE, Brunt E, Oertel WH. Ondansetron treatment of L-dopa-induced psychosis. Neurology 1996; 47(6):1608-1609.
101. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50(1):136-145.
102. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54(12): 2269-2276.
103. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 61(3):324-325.
104. Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002; 23(1):41-43.
105. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002; 25(2):107-110.
106. Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. J Geriatr Psychiatry Neurol 2003; 16(3):184-188.
107. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76(7):934-939.
Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002; 18(5):258-264.
Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16(6):1171-1174.
Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351(24):2509-2518.
Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galan-tamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003; 18(10):937-941. Ozer F, Meral H, Aydin B, et al. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J Ect 2005; 21(2):125-127. Hurwitz TA, Calne DB, Waterman K. Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy. Can J Neurol Sci 1988; 15(1):32-34. Factor SA, Molho ES, Brown DL. Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1995; 7(3):304-307.
Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord 2004; 19(7):831-833. Fernandez HH, Trieschmann ME, Okun MS. Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease. Mov Disord 2005; 20(1):104-105. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997; 244(1):2-8. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004; 61(12):1906-1911.
McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47(5):1113-1124.
Cummings JL. Third International Workshop on Dementia with Lewy Bodies and Parkinson's disease Dementia. Newcastle upon Tyne, United Kingdom: MedReviews, LLC, 2003:31-34.
Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004; 17(3):137-145. McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 1999; 53(5):902-905.
Girotti F, Soliveri P, Carella F, et al. Dementia and cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51(12):1498-1502.
Mayeux R, Stern Y, Rosenstein R, et al. An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol 1988; 45(3):260-262.
Friedman A, Barcikowska M. Dementia in Parkinson's disease. Dementia 1994; 5(1): 12-16.
Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60(3):387-392. Tison F, Dartigues JF, Auriacombe S, et al. Dementia in Parkinson's disease: a population-based study in ambulatory and institutionalized individuals. Neurology 1995; 45(4): 705-708.
Hobson P, Meara J. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age Ageing 1999; 28(1):39-43.
Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 2004; 19(9):1043-1049. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005; 20(10):1255-1263.
Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000; 54(8):1596-1602. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001; 56(6):730-736.
133. Marder K, Tang MX, Cote L, et al. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995; 52(7):695-701.
134. Levy G, Schupf N, Tang MX, et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002; 51(6):722-729.
135. Fernandez HH, Crucian GP, Seignourel P, et al. Laterality, location, type and severity of motor dysfunction may predict cognitive decline in Parkinson's disease. Mov Disord 2005; 20:1243.
136. Levy G, Tang MX, Cote LJ, et al. Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study. Mov Disord 2002; 17(2):250-257.
137. Harhangi BS, de Rijk MC, van Duijn CM, et al. APOE and the risk of PD with or without dementia in a population-based study. Neurology 2000; 54(6):1272-1276.
138. Parsian A, Racette B, Goldsmith LJ, et al. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 2002;79(3):458-461.
139. Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28(4):547-555.
140. Chou KL, Hurtig HI, Stern MB, et al. Diagnostic accuracy of [(99m)Tc]TRODAT-1 SPECT imaging in early Parkinson's disease. Parkinsonism Relat Disord 2004; 10(6):375-379.
141. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38(4):589-598.
142. Rinne JO, Rummukainen J, Paljarvi L, et al. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989; 26(1):47-50.
143. Growdon JH, Kieburtz K, McDermott MP, et al. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group. Neurology 1998; 50(5):1327-1331.
144. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985; 48(5):413-421.
145. Whitehouse PJ, Hedreen JC, White CL 3rd, et al. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983; 13(3):243-248.
146. Mattila PM, Roytta M, Lonnberg P, et al. Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol (Berl) 2001; 102(2):160-166.
147. Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993; 7(2):69-79.
148. Ruberg M, Ploska A, Javoy-Agid F, et al. Muscarinic binding and choline acetyltrans-ferase activity in Parkinsonian subjects with reference to dementia. Brain Res 1982; 232(1):129-139.
149. Cash R, Dennis T, L'Heureux R, et al. Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology 1987; 37(1):42-46.
150. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991; 50(6):743-755.
151. Brown DF, Dababo MA, Bigio EH, et al. Neuropathologic evidence that the Lewy body variant of Alzheimer disease represents coexistence of Alzheimer disease and idiopathic Parkinson disease. J Neuropathol Exp Neurol 1998; 57(1):39-46.
152. Hughes AJ, Daniel SE, Blankson S, et al. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50(2):140-148.
153. Jellinger KA. Morphological substrates of dementia in parkinsonism. A critical update. J Neural Transm Suppl 1997; 51:57-82.
154. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54(10):1916-1921.
155. Ince P, Irving D, MacArthur F, et al. Quantitative neuropathological study of Alzheimertype pathology in the hippocampus: comparison of senile dementia of Alzheimer type, senile dementia of Lewy body type, Parkinson's disease and non-demented elderly control patients. J Neurol Sci 1991; 106(2):142-152.
156. Apaydin H, Ahlskog JE, Parisi JE, et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002; 59(1):102-112.
157. Physicians Desk Reference. 56th ed. Montvale, NJ: Medical Economics Company, Inc., 2002.
158. Whitehouse PJ. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease. Adv Neurol 1987; 45:393-397.
159. Grace J, Daniel S, Stevens T, et al. Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001; 13(2):199-205.
160. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356(9247):2031-2036.
161. Aarsland D, Bronnick K, Karlsen K. Donepezil for dementia with Lewy bodies: a case study. Int J Geriatr Psychiatry 1999; 14(1):69-72.
162. Kaufer DI, Catt KE, Lopez OL, et al. Dementia with Lewy bodies: response of deliriumlike features to donepezil. Neurology 1998; 51(5):1512.
163. Lanctot KL, Herrmann N. Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int J Geriatr Psychiatry 2000; 15(4):338-345.
164. Giladi N, Shabtai H, Gurevich T, et al. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand 2003; 108(5):368-373.
165. Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003; 18(11):988-993.
166. Werber EA, Rabey JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 2001; 108(11):1319-1325.
167. Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72(6):708-712.
168. Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004; 19(1):1-8.
169. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study. Mov Disord 2006; 21(4):456-461.
170. Bedard MA, el Massioui F, Malapani C, et al. Attentional deficits in Parkinson's disease: partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist. Clin Neuropharmacol 1998; 21(2):108-117.
171. Marder K, Tang MX, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998; 50(4):1141-1143.
172. Fernandez HH, Lapane KL. Estrogen use among nursing home residents with a diagnosis of Parkinson's disease. Mov Disord 2000; 15(6):1119-1124.
Was this article helpful?